A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS

Stephen A. Spector, Thomas Weingeist, Richard B Pollard, Douglas T. Dieterich, Tobias Samo, Constance A. Benson, David F. Busch, William R. Freeman, Paul Montague, Henry J. Kaplan, Lois Kellerman, Michael Crager, Bernadette De Armond, William Buhles, Judith Feinberg

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

This prospective, randomized, multicenter, controlled trial was designed to evaluate the efficacy and safety of intravenous ganciclovir for the treatment of peripheral cytomegalovirus (CMV) retinitis in patients with AIDS. Patients were randomly assigned to receive either immediate treatment, intravenous ganciclovir, 5 mg/kg twice daily for 14 days followed by 5 mg/kg once daily for 14 weeks, or deferred treatment. Patients randomized to deferred treatment whose retinitis progressed were offered ganciclovir. Of the 22 patients randomized to deferred treatment who were included in the final analysis, 20 were found to have progressive CMV retinitis compared with 10 of the 13 randomized to immediate treatment. The median time to progression in the deferred treatment group, as determined by a masked fundus photography reading center, was 13.5 days compared with 49.5 days in the immediate treatment group (mean ± SD, 19.3 ± 4.1 vs. 66.4 ± 14.0; P = .001, log rank test). These data indicate that ganciclovir delays the progression of CMV peripheral retinitis in persons with AIDS.

Original languageEnglish (US)
Pages (from-to)557-563
Number of pages7
JournalJournal of Infectious Diseases
Volume168
Issue number3
StatePublished - Sep 1993
Externally publishedYes

Fingerprint

Cytomegalovirus Retinitis
Ganciclovir
Acquired Immunodeficiency Syndrome
Therapeutics
Retinitis
Photography
Multicenter Studies
Reading
Randomized Controlled Trials
Safety

ASJC Scopus subject areas

  • Immunology
  • Public Health, Environmental and Occupational Health

Cite this

Spector, S. A., Weingeist, T., Pollard, R. B., Dieterich, D. T., Samo, T., Benson, C. A., ... Feinberg, J. (1993). A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. Journal of Infectious Diseases, 168(3), 557-563.

A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. / Spector, Stephen A.; Weingeist, Thomas; Pollard, Richard B; Dieterich, Douglas T.; Samo, Tobias; Benson, Constance A.; Busch, David F.; Freeman, William R.; Montague, Paul; Kaplan, Henry J.; Kellerman, Lois; Crager, Michael; De Armond, Bernadette; Buhles, William; Feinberg, Judith.

In: Journal of Infectious Diseases, Vol. 168, No. 3, 09.1993, p. 557-563.

Research output: Contribution to journalArticle

Spector, SA, Weingeist, T, Pollard, RB, Dieterich, DT, Samo, T, Benson, CA, Busch, DF, Freeman, WR, Montague, P, Kaplan, HJ, Kellerman, L, Crager, M, De Armond, B, Buhles, W & Feinberg, J 1993, 'A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS', Journal of Infectious Diseases, vol. 168, no. 3, pp. 557-563.
Spector, Stephen A. ; Weingeist, Thomas ; Pollard, Richard B ; Dieterich, Douglas T. ; Samo, Tobias ; Benson, Constance A. ; Busch, David F. ; Freeman, William R. ; Montague, Paul ; Kaplan, Henry J. ; Kellerman, Lois ; Crager, Michael ; De Armond, Bernadette ; Buhles, William ; Feinberg, Judith. / A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. In: Journal of Infectious Diseases. 1993 ; Vol. 168, No. 3. pp. 557-563.
@article{0feef76ab5f64998955a4ee6d52c76f6,
title = "A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS",
abstract = "This prospective, randomized, multicenter, controlled trial was designed to evaluate the efficacy and safety of intravenous ganciclovir for the treatment of peripheral cytomegalovirus (CMV) retinitis in patients with AIDS. Patients were randomly assigned to receive either immediate treatment, intravenous ganciclovir, 5 mg/kg twice daily for 14 days followed by 5 mg/kg once daily for 14 weeks, or deferred treatment. Patients randomized to deferred treatment whose retinitis progressed were offered ganciclovir. Of the 22 patients randomized to deferred treatment who were included in the final analysis, 20 were found to have progressive CMV retinitis compared with 10 of the 13 randomized to immediate treatment. The median time to progression in the deferred treatment group, as determined by a masked fundus photography reading center, was 13.5 days compared with 49.5 days in the immediate treatment group (mean ± SD, 19.3 ± 4.1 vs. 66.4 ± 14.0; P = .001, log rank test). These data indicate that ganciclovir delays the progression of CMV peripheral retinitis in persons with AIDS.",
author = "Spector, {Stephen A.} and Thomas Weingeist and Pollard, {Richard B} and Dieterich, {Douglas T.} and Tobias Samo and Benson, {Constance A.} and Busch, {David F.} and Freeman, {William R.} and Paul Montague and Kaplan, {Henry J.} and Lois Kellerman and Michael Crager and {De Armond}, Bernadette and William Buhles and Judith Feinberg",
year = "1993",
month = "9",
language = "English (US)",
volume = "168",
pages = "557--563",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS

AU - Spector, Stephen A.

AU - Weingeist, Thomas

AU - Pollard, Richard B

AU - Dieterich, Douglas T.

AU - Samo, Tobias

AU - Benson, Constance A.

AU - Busch, David F.

AU - Freeman, William R.

AU - Montague, Paul

AU - Kaplan, Henry J.

AU - Kellerman, Lois

AU - Crager, Michael

AU - De Armond, Bernadette

AU - Buhles, William

AU - Feinberg, Judith

PY - 1993/9

Y1 - 1993/9

N2 - This prospective, randomized, multicenter, controlled trial was designed to evaluate the efficacy and safety of intravenous ganciclovir for the treatment of peripheral cytomegalovirus (CMV) retinitis in patients with AIDS. Patients were randomly assigned to receive either immediate treatment, intravenous ganciclovir, 5 mg/kg twice daily for 14 days followed by 5 mg/kg once daily for 14 weeks, or deferred treatment. Patients randomized to deferred treatment whose retinitis progressed were offered ganciclovir. Of the 22 patients randomized to deferred treatment who were included in the final analysis, 20 were found to have progressive CMV retinitis compared with 10 of the 13 randomized to immediate treatment. The median time to progression in the deferred treatment group, as determined by a masked fundus photography reading center, was 13.5 days compared with 49.5 days in the immediate treatment group (mean ± SD, 19.3 ± 4.1 vs. 66.4 ± 14.0; P = .001, log rank test). These data indicate that ganciclovir delays the progression of CMV peripheral retinitis in persons with AIDS.

AB - This prospective, randomized, multicenter, controlled trial was designed to evaluate the efficacy and safety of intravenous ganciclovir for the treatment of peripheral cytomegalovirus (CMV) retinitis in patients with AIDS. Patients were randomly assigned to receive either immediate treatment, intravenous ganciclovir, 5 mg/kg twice daily for 14 days followed by 5 mg/kg once daily for 14 weeks, or deferred treatment. Patients randomized to deferred treatment whose retinitis progressed were offered ganciclovir. Of the 22 patients randomized to deferred treatment who were included in the final analysis, 20 were found to have progressive CMV retinitis compared with 10 of the 13 randomized to immediate treatment. The median time to progression in the deferred treatment group, as determined by a masked fundus photography reading center, was 13.5 days compared with 49.5 days in the immediate treatment group (mean ± SD, 19.3 ± 4.1 vs. 66.4 ± 14.0; P = .001, log rank test). These data indicate that ganciclovir delays the progression of CMV peripheral retinitis in persons with AIDS.

UR - http://www.scopus.com/inward/record.url?scp=0027320067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027320067&partnerID=8YFLogxK

M3 - Article

C2 - 8394858

AN - SCOPUS:0027320067

VL - 168

SP - 557

EP - 563

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 3

ER -